| Name | Title | Contact Details |
|---|
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. Foresite Labs Values Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence. Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure. Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions. Simplicity and Focus: Companies die from indigestion, not starvation (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes. Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.
Farkas IRM is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.